Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Axitinib as Neoadjuvant Therapy for Clear Cell Renal Cell Carcinoma
NCT04995016Phase 2Unknown
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, axitinib in clear cell renal cell carcinoma (ccRCC), sponsored by The Second Hospital of Tianjin Medical University. Status: unknown.
02
Drugs
pembrolizumabaxitinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT04995016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04995016.